Intravitreal dexamethasone implants for non-infectious uveitis a review of clinical effectiveness, cost-effectiveness, and guidelines
The purpose of this report is to review the clinical effectiveness, safety, cost-effectiveness of IDI in the treatment of NIU. Of particular interest is evidence on different dose regimens of IDI (e.g., a single implant or two implants with approximately six months between doses, or continual treatm...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, March 25, 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to review the clinical effectiveness, safety, cost-effectiveness of IDI in the treatment of NIU. Of particular interest is evidence on different dose regimens of IDI (e.g., a single implant or two implants with approximately six months between doses, or continual treatment (i.e., three or more implants) or implants at intervals of less than every six months). In addition, this report also reviews the evidence-based guidelines on the treatment of NIU. |
|---|---|
| Physical Description: | 1 PDF file (24 pages) illustration |